Neogen (NEOG) shares came under pressure after the company reported quarterly earnings and revenue that exceeded analyst estimates, but revenue declined 4.4% year on year and trailed peers on growth.
See our latest analysis for Neogen.
At a share price of $9.30, Neogen has a 1-day share price return of 1.09% and a 7-day share price return of 4.97%. The 90-day share price return is down 17.19%, while the 1-year total shareholder return of 49.76% contrasts with a 3-year total shareholder return that is down 49.81%. This suggests recent momentum has improved after a difficult multi year period.
If this earnings reaction has you rethinking where growth could come from next, it may be worth scanning 35 healthcare AI stocks as a starting point for other ideas in related areas.
With the stock still trading below the average analyst price target and a long history of mixed returns, the key question now is whether Neogen is undervalued or whether the market is already pricing in future growth.
Most Popular Narrative: 22.5% Undervalued
With Neogen closing at $9.30 versus a narrative fair value of $12.00, the current price sits well below what this widely followed model implies.
The company's portfolio simplification, divesting lower margin and non core businesses (cleaners and disinfectants, genomics) and focusing on core food safety and animal health verticals, sets the stage for improved net margins and more resilient, higher quality earnings, supported by ongoing deleveraging and reduced operational complexity. Continued investments in R&D and new rapid testing assays (such as the recent launches on the MDS platform), combined with expansion in Europe and other international markets, will allow Neogen to capture share from competitors and participate in the secular growth of high throughput, automated diagnostic solutions, thus boosting both revenue and future earnings potential.
Want to see what kind of revenue trend, margin lift and future earnings multiple are baked into that $12.00 fair value, all discounted at 8.69%? The narrative lays out a detailed path that connects today’s losses, future profitability assumptions and a premium P/E, and it is built on a very specific mix of slower top line expectations and higher margins that might surprise you.
Result: Fair Value of $12 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this story can unravel if integration issues around the 3M Food Safety assets persist or if ongoing weakness in Animal Safety continues to weigh on overall revenue.
Find out about the key risks to this Neogen narrative.
Next Steps
Given the mix of optimism and concern in this story, now is a good time to look at the numbers yourself and pressure test the assumptions behind both outcomes. You can start with the 2 key rewards and 1 important warning sign.
Looking for more investment ideas?
If this earnings story has sharpened your focus, do not stop here. The next step is lining up fresh ideas that match how you like to invest.
- Target growth potential without ignoring quality by scanning screener containing 22 high quality undiscovered gems that may have flown under the radar but still show solid fundamentals.
- Prioritize resilience by checking 64 resilient stocks with low risk scores that score well on stability so short term swings are less likely to knock you off course.
- Build a core watchlist around strength by reviewing the solid balance sheet and fundamentals stocks screener (46 results) that combine financial discipline with room for future decisions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com